|
Volumn 31, Issue 2, 2001, Pages 219-225
|
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
|
Author keywords
[No Author keywords available]
|
Indexed keywords
11 EPIPROSTAGLANDIN F2 ALPHA;
ACETYLSALICYLIC ACID;
CYCLOOXYGENASE 1;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITOR;
LEUKOTRIENE E4;
PLACEBO;
PROSTAGLANDIN D2 DERIVATIVE;
ROFECOXIB;
ADULT;
ARTICLE;
ASTHMA;
BRONCHUS OBSTRUCTION;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSSOVER PROCEDURE;
DOUBLE BLIND PROCEDURE;
DRUG EFFECT;
DRUG SAFETY;
DYSPNEA;
FEMALE;
FORCED EXPIRATORY VOLUME;
HUMAN;
MALE;
PRIORITY JOURNAL;
URINARY EXCRETION;
ADULT;
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;
ASPIRIN;
ASTHMA;
CROSS-OVER STUDIES;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITORS;
CYCLOOXYGENASE INHIBITORS;
DOUBLE-BLIND METHOD;
FEMALE;
FORCED EXPIRATORY VOLUME;
HUMANS;
ISOENZYMES;
LACTONES;
LEUKOTRIENE E4;
MALE;
MEMBRANE PROTEINS;
MIDDLE AGED;
PROSTAGLANDIN D2;
PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;
SULFONES;
|
EID: 0035081699
PISSN: 09547894
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1365-2222.2001.01075.x Document Type: Article |
Times cited : (198)
|
References (32)
|